Introduction
Pfizer is making a significant push into the obesity drug market, with CEO Albert Bourla stating the company is going “all in” on developing its experimental obesity drug. This commitment includes recruiting more experts to help the company make informed decisions
What is Pfizer's "All in" Approach ?
●Focus on Oral Treatments: Pfizer is prioritizing the development of its oral weight-loss pill, danuglipron. They are currently testing multiple doses of a once-a-day version, having previously scrapped a twice-daily version.
●Aiming for Convenience: The goal is to offer a more convenient alternative to injectable drugs like Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy, which currently dominate the market.
●Late-Stage Studies: Pfizer anticipates starting a late-stage study of danuglipron in the second half of this year. Data from dose-testing studies are expected “in a few months”.
●Competitive Market: The market for these drugs is projected to be worth more than $150 billion in annual sales by the early 2030s.
●Second to Market? Pfizer hopes that its pill will be the second oral medication to reach the market, following Eli Lilly’s.
●Acquisition Strategy: While Pfizer is not interested in acquiring an injectable GLP-1 drug because it might be too late to compete in that market, the company is open to acquiring other treatments, including both injectable and oral drugs with different mechanisms
Why is this acquisition important?
Pfizer’s focus on an oral treatment highlights a desire to provide a more convenient option for patients. With the market for weight-loss drugs expected to grow significantly, Pfizer is positioning itself to be a major player
